Risedronate, a novel pyridinyl bisphosphonate for the treatment of osteoporosis and Paget’s disease of bone

Bibliography

• GOA KL, BALFOUR JA: Risedronate. Drugs Aging (1998) 13(0:83-91; discussion 92.
   Google Scholar
• ••A thorough review of the current status of risedronateincluding pharmacodynamics, pharmacokinetics, therapeutic trials and tolerability.
   Google Scholar
• RICHARDSON AC, TINLING SP, CHOLE RA: Risedronate activity in the fetal and neonatal mouse. Otolatyngol Head Neck Surg. (1993) 109(4):623–633.
   PubMed Web of Science ®Google Scholar
• LICATA AA: Bisphosphonate therapy. Am. J. Med. Sci. (1997) 313(0:17–22.
   PubMed Web of Science ®Google Scholar
• ROSS PD, DAVIS JW, VOGEL JM, WASNICH RD: A critical review of bone mass and the risk of fractures in osteoporosis. Ca'cif Tissue. Int. (1990) 46:149–161.
   PubMed Web of Science ®Google Scholar
• MELTON III LJ, ATKINSON EJ, O'FALLON WM, WAHNER HW, RIGGS BL: Long-term fracture prediction by bone mineral assessed at different skeletal sites. J. Bone Miner. Res. (1993) 8:1227–1233.
   PubMed Web of Science ®Google Scholar
• KANIS J, DELMAS P, BURCKHARDT P, COOPER C, TORGENSEN D: Guidelines for diagnosis and manage-ment of osteoporosis. Osteoporos. Int. (1997) 7:390–406.
   PubMed Web of Science ®Google Scholar
• OSTEOPOROSIS SOCIETY OF CANADA: Clinical practice guidelines for the diagnosis and management of osteoporosis. Can. Med. Assoc. J. (1996) 155:1113–1133.
   Web of Science ®Google Scholar
• AMERICAN COLLEGE OF RHEUMATOLOGY: Recommen-dations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. (1996) 39(10:1791–1801.
   PubMedGoogle Scholar
• KANIS J: Drugs used for the treatment of Paget'sdisease. In: Pathophysiology and treatment of Paget's disease of bone. Kanis J (Ed.) Carolina Academic Press, Durham, NC, USA (1990:159–216.
   Google Scholar
• MAUTALEN C, CASCO C, GONZALEZ D et al.: Side effects of disodium aminohydroxypropylidenediphos-phonate (APD) during treatment of bone diseases. Br. Med. J. (1984) 288:828–829.
   PubMed Web of Science ®Google Scholar
• DE GROEN PC, LUBBE DF, HIRSCH LJ et al.: Esophagitis associated with the use of alendronate. New Eng]. J. Med. (1996) 335:1016–1021.
   PubMed Web of Science ®Google Scholar
• DEQUEKER J, WESTHOVENS R: Osteoporosis: a matter of concern to rheumatology! [editorial; review]. Scand. Rheumatol. (1995) 24(3):130–134.
   PubMed Web of Science ®Google Scholar
• MELTON III LJ, WAHNER HW, O'FALLON WM, RIGGS BL: Epidemiology of vertebral fractures in women. Am. J. Epidemic)]. (1989) 129:1000–1011.
   PubMed Web of Science ®Google Scholar
• UNITED STATES BUREAU OF THE CENSUS: Projections of the population of the United States: 1982–2050 (Advance Report) (1982).
   Google Scholar
• MILLER P: Efficacy and safety of cyclical etidronate therapy in the long-term treatment of osteoporosis. Rev. Contemp. Pharmacother. (1998) 9:255–260.
   Web of Science ®Google Scholar
• LUFKIN EG, ARGUETA R, WHITAKER MD et al.: Pamidronate: an unrecognized problem in gastroin-testinal tolerability. Osteoporos Int. (1994) 4 (6):320–322.
   PubMed Web of Science ®Google Scholar
• EASTELL R, REID DM, COMPSTON J et al.: A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J. Intern. Med. (1998) 244 (4):271–292.
   PubMed Web of Science ®Google Scholar
• LIPWORTH BJ: Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch. Intern. Med. (1999) 159(9):941–955.
   PubMed Web of Science ®Google Scholar
• REID IR: Glucocorticoid osteoporosis - mechanisms and management. Eur.J. Endocrinol. (1997) 137:209–217.
   PubMed Web of Science ®Google Scholar
• GEUSENS P, VANHOOF J, STALMANS R et al: Cyclic etidronate increases bone density in the spine and hip in postmenopausal women with on chronic corticos-teroid treatment. A double-blind controlled study. Bone (1997) 20:9S.
   Google Scholar
• PITT P, LI F, TODD P et al.: A double blind placebo controlled study to determine the effects of intermit-tent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment. Thorax (1998) 53 (5):351–356.
   PubMed Web of Science ®Google Scholar
• SAAG KG, EMKEY R, SCHNITZER TJ et al.: Alendronatefor the prevention and treatment of glucocorticoid-induced osteoporosis. New Eng]. J. Med. (1998) 339(5):292–299.
   PubMed Web of Science ®Google Scholar
• GONNELLI S, ROTTOLI P, CEPOLLARO C et al: Preven-tion of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int. (1997) 61 (5):382–385.
   PubMed Web of Science ®Google Scholar
• GALLACHER S, ANDERSON K, SPEEKENBRINK T, BESSENT R, BOYLE I: A comparison of the effects of etidronate, pamidronate, clodronate and calcium on bone density in patients with corticosteroid-dependent lung disease. Calcif Tiss. Int. (1995) 56:447.
   Google Scholar
• THOMAS D, SHEPHERD J: Paget's disease of bone: current concepts in pathogenesis and treatment. J. Oral Pathol Med. (1994) 23(0:12–16.
   PubMed Web of Science ®Google Scholar
• FRASER WD: Paget's disease of bone. Cum Opin. Rheumatol. (1997) 9(4):347–354.
   PubMedGoogle Scholar
• KANIS J: Epidemiology. In: Pathophysiologyand treatment of Paget's disease of bone. Kanis J (Ed.), Martin Dunitz, London (1990:1–12.
   Google Scholar
• GENNARI C, NUTI R, AGNUSDEI D, CAMPOREALE A, MARTINI G: Management of osteoporosis and Paget's disease. Drug Safety (1994) 11(3):179–195.
   PubMed Web of Science ®Google Scholar
• FRANCK W, BRESS N, SINGER F, KRANE S: Rheumaticmanifestations of Paget's disease of bone. Am. J. Med. (1974) 56:592–603.
   PubMed Web of Science ®Google Scholar
• ALTMAN R: Musculoskeletal manifestations of Paget's disease of bone. Arthritis Rheum. (1980) 23:1121–1127.
   PubMed Web of Science ®Google Scholar
• RUSSELL R, SMITH R, PRESTON C et al.: Diphosphonates in Paget's disease. Lancet (1974) i:894–898.
   Google Scholar
• ALTMAN RD, JOHNSTON JR CC, KHAIRI MR et al.: Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). New Engl. J. Med. (1973) 289 (26):1379–1384.
   PubMed Web of Science ®Google Scholar
• CANFIELD R, ROSNER W, SKINNER J et al.: Diphos-phonate therapy of Paget's disease of bone. J. Clin. Endocrinol. Metab. (1977) 44(0:96–106.
   PubMedGoogle Scholar
• BOYCE BF, SMITH L, FOGELMAN I et al.: Focalosteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet (1984) 1(8380:821–824.
   PubMedGoogle Scholar
• ALEXANDRE C, MEUNIER PJ, EDOUARD C, KHAIRI RA, JOHNSTON CC: Effects of ethane-1 hydroxy-1, 1-diphosphonate (5 mg/kg/day dose) on quantitative bone histology in Paget's disease of bone. Metab. Bone Dis. Relat. Res. (1981) 3(4-5):309–315.
   PubMedGoogle Scholar
• DEWIS P, PRASAD BK, ANDERSON DC, WILLETS S: Clinical experience with the use of two diphosphon-ates in the treatment of Paget's disease. Ann. Rheum. Dis. (1985) 44(1):34–38.
   PubMed Web of Science ®Google Scholar
• HARINCK HI, BIJVOET OL, BLANKSMA HJ, DAHLING-HAUS NIENHUYS PJ: Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone. Clin. Orthop. (1987) 217:79–98.
   PubMedGoogle Scholar
• HEYNEN G, DELWAIDE P, BIJVOET OLM, FRANCHIMONTP: Clinical and biological effects of low doses of (3 amino-1 hydroxypropylidene)-1,1-bisphosphonate (APD) in Paget's disease of bone. Eur. J. Clin. Invest. (1982) 12:29–35.
   PubMed Web of Science ®Google Scholar
• KHAN SA, VASIKARAN S, MCCLOSKEY EV et al.: Alendronate in the treatment of Paget's disease of bone. Bone (1997) 20(3):263–271.
   PubMed Web of Science ®Google Scholar
• REID IR, NICHOLSON GC, WEINSTEIN RS et al.:Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a random-ized, placebo-controlled trial [published erratum appears in Am. J. Med. 1997 Mar;102 (3):322]. Am] Med. (1996) 1O1(4):341–348.
   Google Scholar
• SIETSEMA WK, EBETINO FH, SALVAGNO AM, BEVAN JA:Antiresorptive dose-response relationships across three generations of bisphosphonates. Drugs Exp. Clin. Res. (1989) 15:389–396.
   PubMedGoogle Scholar
• WATTS N, HANGARTNER T, CHESNUT C et al.: Risedronate treatment prevents vertebral and non-vertebral fractures in women with postmeno-pausal osteoporosis. Calc. Tiss. Int. (1999) 64 (Suppl. 1):S42.
   Google Scholar
• EASTELL R, MINNE H, SORENSEN 0 et al.: Risedronate reduces fracture risk in women with established postmenopausal osteoporosis. Cala Tiss. Int (1999) 64 (Suppl. 1):S43.
   Google Scholar
• ••Large-scale trial demonstrating the efficacy of risedronate inreducing the risk of vertebral fractures.
   Google Scholar
• FOGELMAN I, RIBOT C, SMITH R et al: Risedronateproduces dose-dependent increases in bone mineral density in postmenopausal women with low bone mass. Calc. Tiss. Int. (1999) 64 (Suppl. 1):S69.
   Google Scholar
• MCCLUNG MR, BENSEN W, BOLOGNESE MA et al.: Risedronate increases BMD at the hip, spine and radius in postmenopausal women with low bone mass. J. Bone Miner. Res. (1997) 12:S169.
   Google Scholar
• •Risedronate therapy achieved dose-proportional increases in BMD at the hip and spine after 18 months' treatment with risedronate 2.5 mg/day or 5 mg/day.
   Google Scholar
• COHEN S, LEVY R, KELLER M et al.: Risedronate preventscorticosteroid-induced bone loss and decreases the risk of vertebral fractures. Arthritis Rheum. (1998) 41:S137.
   Web of Science ®Google Scholar
• REID D, DEVOGELAER J, HUGHES R et al.: Risedronate iseffective and well tolerated in treating corticosteroid-induced osteoporosis. Arthritis Rheum. (1998) 41:S303.
   Web of Science ®Google Scholar
• ERIKSEN E, BROWN J, BOILING E et al.: Beneficial effectsof risedronate in corticosteroid-treated patients: histology and histomorphometry. Bone (1998) 23 (Suppl. 5):W468.
   Google Scholar
• EASTELL R, DEVOGELAER J, PEEL N et al.: A double-blindplacebo-controlled study to determine the effects of risedronate on bone loss in glucocorticoid-treated rheumatoid arthritis. Osteoporosis: Proceedings of the 1996 World Congress on Osteoporosis, Amsterdam, The Netherlands (1996):391–393
   Google Scholar
• SINGER FR, CLEMENS TL, EUSEBIO RA, BEKKER PJ:Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease. J. Clin. Endocrinol. Metab. (1998) 83(6):1906–1910.
   PubMed Web of Science ®Google Scholar
• •Risedronate 30 mg/day is highly effective at inducing a rapid reduction in biochemical markers of disease activity.
   Google Scholar
• HOSKING DJ, EUSEBIO RA, CHINES AA: Paget's disease of bone: reduction of disease activity with oral risedronate. Bone (1998) 22:51–55.
   PubMed Web of Science ®Google Scholar
• •Normalisation of AP in most patients with severe Paget's disease. Pagetic bone pain was reduced.
   Google Scholar
• SIRIS ES, CHINES AA, ALTMAN RD et al: Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J. Bone Miner. Res. (1998) 13(6):1032–1038.
   PubMed Web of Science ®Google Scholar
• ••Risedronate can significantly reduce biochemical markers ofbone resorption and pain associated with Paget's disease.
   Google Scholar
• BROWN JP, HOSKING DJ, STE-MARIE L et al.: Risedronate, a highly effective, short-term oral treatment for Paget's disease: a dose-response study. Cala Tiss. Int. (1999) 64(2):93–99.
   PubMed Web of Science ®Google Scholar
• •Dose-ranging study in patients with Paget's disease - the greatest response to therapy was in patients who received 30 mg/day.
   Google Scholar
• MILLER PD, BROWN JP, SIRIS ES et al: A prospective, multicenter, randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Am. J. Med. (1999) (In press).
   Google Scholar
• ••Phase III study comparing the efficacy of risedronate andetidronate in treating patients with Paget's disease.
   Google Scholar
• WALLACH S, SIRIS E, SINGER F et al. Risedronate produces sustained remission in patients with Paget's disease of bone. Bone (1998) 23( Suppl 5) Abstract F181
   Google Scholar
• MORTENSEN L, CHARLES P, BEKKER PJ, DIGENNARO J,JOHNSTON JR CC: Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J. Clin. Endocrinol. Metab. (1998) 83(2)396–402.
   Google Scholar
• SINGER FR, BROWN JP, SIRIS ES et al.: A safety review ofthe use of risedronate in the treatment of Paget's disease of bone. Arthritis Rheum. (1997) S279.
   Google Scholar
• ADAMI S, BHALLA AK, DORIZZI R et al.: The acute-phase response after bisphosphonate administration. Cala Tiss. mt. (1987) 41 (6):326–331.
   PubMed Web of Science ®Google Scholar
• SACCO-GIBSON N, MITCHELL DY, EUSEBIO RA, AXELROD DW, POWELL JH: Risedronate (a pyridinyl bisphosphonate) does not induce acute phase reaction after single and multiple dose, intravenous administration. Bone (1997) 20:102S.
   Google Scholar
• WARD C, SACCO-GIBSON N, MITCHELL DY, KELLY S: Single dose risedronate (pyridinyl-bisphosphonate) does not induce acute phase reaction in healthy subjects. J. Bone Miner. Res. (1997) 11:S346.
   Google Scholar
• MITCHELL DY, ST.PETER JV, EUSEBIO RA et al.: The effect of renal impairment on risedronate pharmacoki-netics. j Bone Miner. Res. (1997) 12:S344.
   Google Scholar
• NECCIARI J, MOUGEOT V, PINQUER JL, ARNOUX P, DELAUTURE D: Influence of food intake (hypocalcic or normal meal) on the bioavailability of tiludronate. 5th World Conference on Clinical Pharmacology and Therapeu-tics. Yokohama, Japan (1992):P–305–309.
   Google Scholar
• MITCHELL DY, HEISE MA, PALLONE KA et al.: The effect of dosing regimen on the pharmacokinetics of risedronate. Br. J. Clin. Pharmacol. (1999) (In press).
   Google Scholar
• GERTZ BJ, HOLLAND SD, KLINE WF, MATUSZEWSKI BK, PORRAS AG: Clinical pharmacology of alendronate sodium. Osteoporosis Int. (1993) 3:S13–S16.
   PubMed Web of Science ®Google Scholar
• MADERA A, LICATA AA: Alendronate increases bone density in patients previously treated with cyclical etidronate. Endocrine Society (1998).
   Google Scholar